Literature DB >> 12637616

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

Karl Peggs, Stephen Mackinnon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12637616     DOI： 10.1056/NEJMe030009

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  28 in total

1.  Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors:  Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

2.  Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.

Authors:  B H Srinivas; T Roshni Paul; Shantveer G Uppin; Megha S Uppin; Rachel T Jacob; D Raghunadharao
Journal:  Indian J Hematol Blood Transfus       Date:  2012-01-31       Impact factor: 0.900

3.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

4.  Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.

Authors:  In Sock Jang; Elias Chaibub Neto; Juistin Guinney; Stephen H Friend; Adam A Margolin
Journal:  Pac Symp Biocomput       Date:  2014

5.  Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.

Authors:  Katsuya Ikuta; Yoshihiro Torimoto; Junko Jimbo; Junki Inamura; Motohiro Shindo; Kazuya Sato; Yoshihiko Tokusashi; Naoyuki Miyokawa; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

6.  Central nervous system blast crisis in chronic myeloid leukemia on imatinib mesylate therapy: report of two cases.

Authors:  Narayan Radhika; Mishra Minakshi; Mohanty Rajesh; Baisakh R Manas; Mishra Deepak Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-08       Impact factor: 0.900

7.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

Review 8.  Leukemic stem cells: where do they come from?

Authors:  Emmanuelle Passegué; Irving L Weisman
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

9.  PDGFR-α inhibition preserves blood-brain barrier after intracerebral hemorrhage.

Authors:  Qingyi Ma; Bin Huang; Nikan Khatibi; William Rolland; Hidenori Suzuki; John H Zhang; Jiping Tang
Journal:  Ann Neurol       Date:  2011-12       Impact factor: 10.422

10.  Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.

Authors:  N Singh; L Kumar; R Meena; T Velpandian
Journal:  Eur J Clin Pharmacol       Date:  2009-02-12       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.